{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:45:00Z","timestamp":1790829900221,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018696","name":"R\u00e9gion Normandie","doi-asserted-by":"publisher","award":["ORGATHEREX"],"award-info":[{"award-number":["ORGATHEREX"]}],"id":[{"id":"10.13039\/501100018696","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canceropole Nord-Ouest, France","award":["ORGRAFT"],"award-info":[{"award-number":["ORGRAFT"]}]},{"DOI":"10.13039\/100007380","name":"Fondation de l\u2019Avenir","doi-asserted-by":"crossref","award":["AP-RM-19-020"],"award-info":[{"award-number":["AP-RM-19-020"]}],"id":[{"id":"10.13039\/100007380","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["PJA20191209649"],"award-info":[{"award-number":["PJA20191209649"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian cancer is the first cause of death from gynecological malignancies mainly due to development of chemoresistance. Despite the emergence of PARP inhibitors, which have revolutionized the therapeutic management of some of these ovarian cancers, the 5-year overall survival rate remains around 45%. Therefore, it is crucial to develop new therapeutic strategies, to identify predictive biomarkers and to predict the response to treatments. In this context, functional assays based on patient-derived tumor models could constitute helpful and relevant tools for identifying efficient therapies or to guide clinical decision making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>The OVAREX study is a single-center non-interventional study which aims at investigating the feasibility of establishing in vivo and ex vivo models and testing ex vivo models to predict clinical response of ovarian cancer patients. Patient-Derived Xenografts (PDX) will be established from tumor fragments engrafted subcutaneously into immunocompromised mice. Explants will be generated by slicing tumor tissues and Ascites-Derived Spheroids (ADS) will be isolated following filtration of ascites. Patient-derived tumor organoids (PDTO) will be established after dissociation of tumor tissues or ADS, cell embedding into extracellular matrix and culture in specific medium. Molecular and histological characterizations will be performed to compare tumor of origin and paired models. Response of ex vivo tumor-derived models to conventional chemotherapy and PARP inhibitors will be assessed and compared to results of companion diagnostic test and\/or to the patient\u2019s response to evaluate their predictive value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This clinical study aims at generating PDX and ex vivo models (PDTO, ADS, and explants) from tumors or ascites of ovarian cancer patients who will undergo surgical procedure or paracentesis. We aim at demonstrating the predictive value of ex vivo models for their potential use in routine clinical practice as part of precision medicine, as well as establishing a collection of relevant ovarian cancer models that will be useful for the evaluation of future innovative therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The clinical trial has been validated by local research ethic committee on January 25th 2019 and registered at ClinicalTrials.gov with the identifier NCT03831230 on January 28th 2019, last amendment v4 accepted on July 18, 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-024-12429-w","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T06:01:59Z","timestamp":1717740119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers"],"prefix":"10.1186","volume":"24","author":[{"given":"Lucie","family":"Thorel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordane","family":"Divoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Lequesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Babin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Marie","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romane","family":"Florent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Desmartin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Lecouflet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Marde Alagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Briand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Rouzier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9opold","family":"Gaichies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Martin-Fran\u00e7oise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Le Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Denoyelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Vigneron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Jeanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Blanc-Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Leman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Vaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Figeac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Meryet-Figuiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Bastien","family":"Weiswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enora","family":"Dolivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"issue":"1","key":"12429_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ygyno.2019.12.047","volume":"157","author":"CJ Cabasag","year":"2020","unstructured":"Cabasag CJ, Butler J, Arnold M, Rutherford M, Bardot A, Ferlay J, et al. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): a population-based study. Gynecol Oncol avr. 2020;157(1):234\u201344.","journal-title":"Gynecol Oncol avr"},{"issue":"2","key":"12429_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ygyno.2018.06.002","volume":"150","author":"D Torres","year":"2018","unstructured":"Torres D, Wang C, Kumar A, Bakkum-Gamez JN, Weaver AL, McGree ME, et al. Factors that influence survival in high-grade serous ovarian cancer: a complex relationship between molecular subtype, disease dissemination, and operability. Gynecol Oncol ao\u00fbt. 2018;150(2):227\u201332.","journal-title":"Gynecol Oncol ao\u00fbt"},{"issue":"4","key":"12429_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"12429_CR4","first-page":"3080","volume":"128","author":"C Marth","year":"2022","unstructured":"Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, et al. Real-life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial). Cancer 15 ao\u00fbt. 2022;128(16):3080\u20139.","journal-title":"Cancer 15 ao\u00fbt"},{"key":"12429_CR5","doi-asserted-by":"crossref","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 29 d\u00e9c. 2011;365(26):2484\u201396.","DOI":"10.1056\/NEJMoa1103799"},{"issue":"7","key":"12429_CR6","doi-asserted-by":"publisher","first-page":"12389","DOI":"10.18632\/oncotarget.13310","volume":"8","author":"L Rossi","year":"2017","unstructured":"Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, et al. Bevacizumab in ovarian cancer: a critical review of phase III studies. Oncotarget 14 f\u00e9vr. 2017;8(7):12389\u2013405.","journal-title":"Oncotarget 14 f\u00e9vr"},{"key":"12429_CR7","doi-asserted-by":"crossref","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 29 d\u00e9c. 2011;365(26):2473\u201383.","DOI":"10.1056\/NEJMoa1104390"},{"issue":"9","key":"12429_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V, Tutt A, Balma\u00f1a J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol Sept. 2019;30(9):1437\u201347.","journal-title":"Ann Oncol Sept"},{"issue":"25","key":"12429_CR9","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer. N Engl J Med 19 d\u00e9c. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med 19 d\u00e9c"},{"issue":"21","key":"12429_CR10","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1158\/1078-0432.CCR-23-0898","volume":"29","author":"R Leman","year":"2023","unstructured":"Leman R, Muller E, Legros A, Goardon N, Chentli I, Atkinson A, et al. Validation of the clinical use of GIScar, an academic-developed genomic instability score Predicting sensitivity to maintenance Olaparib for Ovarian Cancer. Clin Cancer Res 1 nov. 2023;29(21):4419\u201329.","journal-title":"Clin Cancer Res 1 nov"},{"issue":"1","key":"12429_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41416-021-01295-z","volume":"125","author":"PM Morice","year":"2021","unstructured":"Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L. Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. Br J Cancer Juill. 2021;125(1):7\u201314.","journal-title":"Br J Cancer Juill"},{"issue":"1","key":"12429_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 10 janv. 2022;40(1):26\u201335.","journal-title":"Cancer Cell 10 janv"},{"key":"12429_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.11.005","volume":"24","author":"NG Alkema","year":"2016","unstructured":"Alkema NG, Wisman GBA, van der Zee AGJ, van Vugt MATM, de Jong S. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resist Updat janv. 2016;24:55\u201369.","journal-title":"Drug Resist Updat janv"},{"issue":"11","key":"12429_CR14","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1051\/medsci\/2022148","volume":"38","author":"L Thorel","year":"2022","unstructured":"Thorel L, Florent R, Perr\u00e9ard M, Vincent A, Poulain L, Weiswald LB. [Patient-derived tumor organoids (or tumoroid), a growing preclinical model for oncology]. Med Sci (Paris) Nov. 2022;38(11):880\u20137.","journal-title":"Med Sci (Paris) Nov"},{"issue":"1","key":"12429_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2014.12.004","volume":"17","author":"LB Weiswald","year":"2015","unstructured":"Weiswald LB, Bellet D, Dangles-Marie V. Spherical cancer models in tumor biology. Neoplasia janv. 2015;17(1):1\u201315.","journal-title":"Neoplasia janv"},{"issue":"5","key":"12429_CR16","first-page":"E340","volume":"136","author":"S Lheureux","year":"2015","unstructured":"Lheureux S, N\u2019Diaye M, Blanc-Fournier C, Dugu\u00e9 AE, Clarisse B, Dutoit S, et al. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma. Int J Cancer 1 mars. 2015;136(5):E340\u2013350.","journal-title":"Int J Cancer 1 mars"},{"key":"12429_CR17","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1038\/ncomms7169","volume":"6","author":"B Majumder","year":"2015","unstructured":"Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun 27 f\u00e9vr. 2015;6:6169.","journal-title":"Nat Commun 27 f\u00e9vr"},{"issue":"18","key":"12429_CR18","doi-asserted-by":"publisher","first-page":"8352","DOI":"10.1073\/pnas.0907676107","volume":"107","author":"V Vaira","year":"2010","unstructured":"Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S 4 mai. 2010;107(18):8352\u20136.","journal-title":"Proc Natl Acad Sci U S 4 mai"},{"issue":"11","key":"12429_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","volume":"19","author":"ER Zanella","year":"2022","unstructured":"Zanella ER, Grassi E, Trusolino L. Towards precision oncology with patient-derived xenografts. Nat Rev Clin Oncol Nov. 2022;19(11):719\u201332.","journal-title":"Nat Rev Clin Oncol Nov"},{"issue":"10","key":"12429_CR20","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","volume":"28","author":"E Izumchenko","year":"2017","unstructured":"Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol 1 oct. 2017;28(10):2595\u2013605.","journal-title":"Ann Oncol 1 oct"},{"key":"12429_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.gde.2013.11.012","volume":"24","author":"N Sachs","year":"2014","unstructured":"Sachs N, Clevers H. Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev f\u00e9vr. 2014;24:68\u201373.","journal-title":"Curr Opin Genet Dev f\u00e9vr"},{"issue":"10","key":"12429_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrm2236","volume":"8","author":"F Pampaloni","year":"2007","unstructured":"Pampaloni F, Reynaud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol oct. 2007;8(10):839\u201345.","journal-title":"Nat Rev Mol Cell Biol oct"},{"issue":"1","key":"12429_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer Juill. 2020;123(1):9\u201316.","journal-title":"Br J Cancer Juill"},{"issue":"10","key":"12429_CR24","doi-asserted-by":"publisher","first-page":"e46858","DOI":"10.1371\/journal.pone.0046858","volume":"7","author":"A Latifi","year":"2012","unstructured":"Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS ONE. 2012;7(10):e46858.","journal-title":"PLoS ONE"},{"issue":"9","key":"12429_CR25","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ccell.2021.07.020","volume":"39","author":"V Veninga","year":"2021","unstructured":"Veninga V, Voest EE. Tumor organoids: opportunities and challenges to guide precision medicine. Cancer Cell 13 sept. 2021;39(9):1190\u2013201.","journal-title":"Cancer Cell 13 sept"},{"key":"12429_CR26","doi-asserted-by":"crossref","unstructured":"Thorel L, Morice PM, Paysant H, Florent R, Babin G, Thomine C, et al. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma. J Exp Clin Cancer Res. oct 2023;7(1):260.","DOI":"10.1186\/s13046-023-02809-8"},{"issue":"5","key":"12429_CR27","first-page":"1","volume":"11","author":"R Florent","year":"2020","unstructured":"Florent R, Weiswald LB, Lambert B, Brotin E, Abeilard E, Louis MH, et al. Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib. Cell Death Dis 18 mai. 2020;11(5):1\u201316.","journal-title":"Cell Death Dis 18 mai"},{"key":"12429_CR28","doi-asserted-by":"crossref","unstructured":"Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, et al. Generation of Tumor-reactive T cells by co-culture of Peripheral Blood lymphocytes and Tumor Organoids. Cell. sept 2018;6(6):1586\u2013e159812.","DOI":"10.1016\/j.cell.2018.07.009"},{"issue":"1","key":"12429_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-022-10466-x","volume":"23","author":"M Perr\u00e9ard","year":"2023","unstructured":"Perr\u00e9ard M, Florent R, Divoux J, Grellard JM, Lequesne J, Briand M, et al. ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies. BMC Cancer d\u00e9c. 2023;23(1):1\u20139.","journal-title":"BMC Cancer d\u00e9c"},{"key":"12429_CR30","doi-asserted-by":"crossref","unstructured":"de Witte CJ, Espejo Valle-Inclan J, Hami N, L\u00f5hmussaar K, Kopper O, Vreuls CPH et al. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses. Cell Reports. 16 juin. 2020;31(11):107762.","DOI":"10.1016\/j.celrep.2020.107762"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12429-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T06:03:40Z","timestamp":1717740220000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12429-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12429"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12429-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has received ethical approval from the Comit\u00e9 de Protection des Personnes Est IV (N\u00b0EudraCT: 2018-A02152-53) in January 2019 with last amendment (V4) accepted in March 2023. This committee is independent and not related with any affiliation of the authors. Any subsequent will of modification of the protocol would be submitted to agreement of the committee. The clinical trial has been registered at ClinicalTrials.gov with the identifier NCT03831230 on January 28th, 2019. The study will be explained to the patients by the surgeons or the oncologists, who will give them an information file. All patients will consent to be part of the study by giving their informed non-opposition.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"701"}}